Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2016-06-27 Regulatory Filings
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobis Elocta® (rFVIIIFc) godkänd i Schweiz för behandling av hemofili A
Regulatory Filings Classification · 95% confidence The document is a press release from Swedish Orphan Biovitrum AB (Sobi) announcing that its drug Elocta has received approval from the Swissmedic authority in Switzerland for treating hemophilia A. This type of announcement, detailing a regulatory approval, product update, or significant corporate news that is not a full financial report (like 10-K or IR) or a transcript, typically falls under general regulatory announcements or news releases. Since it is a specific announcement about a regulatory event (drug approval) and not a standard financial filing, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory announcement, or potentially an 'Earnings Release' (ER) if it were tied to financial reporting, but here it is clearly product/regulatory news. Given the options, RNS serves as the best fit for a non-standard, specific regulatory/corporate news announcement that isn't a formal financial report or management discussion.
2016-06-27 Swedish
Sobi tar upp ny kreditfacilitet och förtidslöser obligationslån 2012/2017 på 800 Mkr
Capital/Financing Update Classification · 98% confidence The document is a press release dated May 27, 2016, announcing that Swedish Orphan Biovitrum AB (Sobi) is setting up a new credit facility and will early redeem (call) its outstanding bond loan of 800 Mkr due in 2017. This action involves significant financing and capital structure changes (taking on new debt to retire old debt). This clearly falls under the definition of 'Capital/Financing Update' (CAP), as it details the arrangement of new credit facilities and the early repayment of existing debt instruments.
2016-05-27 Swedish
Sobi enters new credit facility and redeems SEK 800 M bond loan 2012/2017 prior to final maturity
Capital/Financing Update Classification · 98% confidence The document text announces that Sobi is entering a new credit facility and redeeming a SEK 800 million bond loan prior to maturity. This involves securing new financing (SEK 1 billion facilities agreement) and repaying existing debt. This action directly relates to the company's capital structure and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document is a press release format, but the core subject matter is financing, not just announcing the release of another report (RPA) or general regulatory news (RNS).
2016-05-27 English
Resolutions from Swedish Orphan Biovitrum AB’s (Sobi™) Annual General Meeting (AGM)
AGM Information Classification · 100% confidence The document explicitly states in the title and content that it contains the 'Resolutions from Swedish Orphan Biovitrum AB's (Sobi™) Annual General Meeting (AGM)'. It details the outcomes of votes on board elections, remuneration, and capital structure changes (share issuance authorizations) that occurred during the AGM. This directly corresponds to the definition of AGM Information.
2016-05-24 English
Kommuniké från Swedish Orphan Biovitrum ABs (Sobi™)årsstämma
AGM Information Classification · 100% confidence The document is explicitly titled "Kommuniké från Swedish Orphan Biovitrum ABs (Sobi™) årsstämma" which translates to 'Communiqué from the Annual General Meeting (AGM) of Swedish Orphan Biovitrum AB (Sobi™)'. It details the decisions made at the AGM, including the approval of financial statements, election/re-election of board members, approval of remuneration guidelines, and decisions regarding incentive programs and share issuances. This content directly corresponds to the purpose of an Annual General Meeting communication. Therefore, the classification is AGM-R.
2016-05-24 Swedish
Sobis vd avyttrar del av incitamentsaktier
Remuneration Information Classification · 99% confidence The document is a press release ("PRESSMEDDELANDE") dated May 16, 2015, announcing that the CEO, Geoffrey McDonough, sold a portion of his incentive shares. The text explicitly details the transaction, the reason (covering US tax obligations for a 2013 incentive program and preparing for a 2016 program), and the resulting share ownership. This type of announcement, reporting personal share transactions by company directors and executives (insider trades), directly matches the definition for Director's Dealing (DIRS). It is not a general regulatory filing (RNS) because it is highly specific to insider trading activity.
2016-05-16 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.